journal
https://read.qxmd.com/read/38548349/development-of-a-cd163-targeted-pet-radiotracer-that-images-resident-macrophages-in-atherosclerosis
#41
JOURNAL ARTICLE
Xiuli Zhang, Gyu Seong Heo, Alexandria Li, Divangana Lahad, Lisa Detering, Joan Tao, Xuefeng Gao, Xiaohui Zhang, Hannah Luehmann, Deborah Sultan, Lanlan Lou, Rajiu Venkatesan, Ran Li, Jie Zheng, Junedh Amrute, Chieh-Yu Lin, Benjamin J Kopecky, Robert J Gropler, Andrea Bredemeyer, Kory Lavine, Yongjian Liu
Tissue-resident macrophages are complementary to proinflammatory macrophages to promote the progression of atherosclerosis. The noninvasive detection of their presence and dynamic variation will be important to the understanding of their role in the pathogenesis of atherosclerosis. The goal of this study was to develop a targeted PET radiotracer for imaging CD163-positive (CD163+) macrophages in multiple mouse atherosclerosis models and assess the potential of CD163 as a biomarker for atherosclerosis in humans...
March 28, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38548348/cancer-risk-in-graves-disease-with-radioactive-131-i-treatment-a-nationwide-cohort-study
#42
JOURNAL ARTICLE
Kyeong Jin Kim, Jimi Choi, Kyoung Jin Kim, Eyun Song, Ji Hee Yu, Nam Hoon Kim, Hye Jin Yoo, Ji A Seo, Nan Hee Kim, Kyung Mook Choi, Sei Hyun Baik, Sin Gon Kim
Radioactive 131 I (RAI) therapy has potential effects for the treatment of Graves disease (GD). However, whether RAI therapy for GD increases cancer risk remains controversial in medicine and public health. We aimed to investigate whether the risk of cancer increases in patients with GD receiving RAI therapy compared with those who did not. Methods: We used the Korean National Health Insurance Service's National Health Information Database from 2004 to 2020 and defined GD as prescribing antithyroid drugs, RAI, or thyroidectomy as a treatment for GD ( International Classification of Diseases, 10th revision, E05 group)...
March 28, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38548347/high-temporal-resolution-kinetic-modeling-of-lung-tumors-with-dual-blood-input-function-using-total-body-dynamic-pet
#43
JOURNAL ARTICLE
Yiran Wang, Yasser G Abdelhafez, Benjamin A Spencer, Rashmi Verma, Mamta Parikh, Nicholas Stollenwerk, Lorenzo Nardo, Terry Jones, Ramsey D Badawi, Simon R Cherry, Guobao Wang
The lungs are supplied by both the pulmonary arteries carrying deoxygenated blood originating from the right ventricle and the bronchial arteries carrying oxygenated blood downstream from the left ventricle. However, this effect of dual blood supply has never been investigated using PET, partially because the temporal resolution of conventional dynamic PET scans is limited. The advent of PET scanners with a long axial field of view, such as the uEXPLORER total-body PET/CT system, permits dynamic imaging with high temporal resolution (HTR)...
March 28, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38514088/effectiveness-and-safety-of-retreatment-with-177-lu-dotatate-in-patients-with-progressive-neuroendocrine-tumors-a-retrospective-real-world-study-in-the-united-states
#44
JOURNAL ARTICLE
Ebrahim S Delpassand, Soheil M Yazdi, Shashank Ghantoji, Antonio Nakasato, Corinne Strickland, Rodolfo Nunez, Afshin Shafie, Susan Cork, Clare Byrne, Jackson Tang, Jeetvan Patel
Advanced neuroendocrine tumors (NETs) are associated with a poor prognosis. A regimen of 4 cycles of 177 Lu-DOTATATE has been shown to improve both progression-free survival (PFS) and overall survival (OS) in patients with advanced NETs. To the best of our knowledge, this is the first study in the United States to evaluate the effectiveness and safety of additional cycles of 177 Lu-DOTATATE therapy in patients with progressive NETs. Methods: This was a retrospective chart review of adults with advanced NETs...
March 21, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38514087/impact-of-18-f-fdg-pet-intensity-normalization-on-radiomic-features-of-oropharyngeal-squamous-cell-carcinomas-and-machine-learning-generated-biomarkers
#45
JOURNAL ARTICLE
Stefan P Haider, Tal Zeevi, Kariem Sharaf, Moritz Gross, Amit Mahajan, Benjamin H Kann, Benjamin L Judson, Manju L Prasad, Barbara Burtness, Mariam Aboian, Martin Canis, Christoph A Reichel, Philipp Baumeister, Seyedmehdi Payabvash
We aimed to investigate the effects of 18 F-FDG PET voxel intensity normalization on radiomic features of oropharyngeal squamous cell carcinoma (OPSCC) and machine learning-generated radiomic biomarkers. Methods: We extracted 1,037 18 F-FDG PET radiomic features quantifying the shape, intensity, and texture of 430 OPSCC primary tumors. The reproducibility of individual features across 3 intensity-normalized images (body-weight SUV, reference tissue activity ratio to lentiform nucleus of brain and cerebellum) and the raw PET data was assessed using an intraclass correlation coefficient (ICC)...
March 21, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38514086/gerald-l-denardo-md-1932-2024
#46
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
March 21, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38514085/-18-f-fet-pet-mri-an-accurate-technique-for-detection-of-small-functional-pituitary-tumors
#47
JOURNAL ARTICLE
Ilanah J Pruis, Frederik A Verburg, Rutger K Balvers, Anita A Harteveld, Richard A Feelders, Meike W Vernooij, Marion Smits, Sebastian J C M M Neggers, Sophie E M Veldhuijzen van Zanten
Small functional pituitary tumors can cause severely disabling symptoms and early death. The gold standard diagnostic approach includes laboratory tests and MRI, with or without inferior petrosal sinus sampling (IPSS). In up to 40% of patients, however, the source of excess hormone production remains unidentified or uncertain. This excludes patients from surgical, Gamma Knife, and CyberKnife therapy and adversely affects overall cure rates. We here assess the diagnostic yield of O -(2-[18 F]fluoroethyl)-l-tyrosine ([18 F]FET) PET/MRI for detection of small functional pituitary tumors in these patients...
March 21, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38514084/noninvasively-deciphering-the-immunosuppressive-tumor-microenvironment-using-galectin-1-pet-to-inform-immunotherapy-responses
#48
JOURNAL ARTICLE
Ning Liu, Xiujie Yang, Chao Gao, Jianze Wang, Yuwen Zeng, Linyu Zhang, Qi Yin, Ting Zhang, Haoyi Zhou, Kui Li, Jinhong Du, Shixin Zhou, Xuyang Zhao, Hua Zhu, Zhi Yang, Zhaofei Liu
Immune checkpoint blockade (ICB) has achieved groundbreaking results in clinical cancer therapy; however, only a subset of patients experience durable benefits. The aim of this study was to explore strategies for predicting tumor responses to optimize the intervention approach using ICB therapy. Methods: We used a bilateral mouse model for proteomics analysis to identify new imaging biomarkers for tumor responses to ICB therapy. A PET radiotracer was synthesized by radiolabeling the identified biomarker-targeting antibody with 124 I...
March 21, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38514083/preclinical-characterization-of-dpi-4452-a-68-ga-177-lu-theranostic-ligand-for-carbonic-anhydrase-ix
#49
JOURNAL ARTICLE
Frédéric Massière, Norbert Wiedemann, Inês Borrego, Aileen Hoehne, Frank Osterkamp, Matthias Paschke, Dirk Zboralski, Anne Schumann, Anne Bredenbeck, Franck Brichory, Antoine Attinger
The membrane protein carbonic anhydrase IX (CAIX) is highly expressed in many hypoxic or von Hippel-Lindau tumor suppressor-mutated tumor types. Its restricted expression in healthy tissues makes CAIX an attractive diagnostic and therapeutic target. DPI-4452 is a CAIX-targeting cyclic peptide with a DOTA cage, allowing radionuclide chelation for theranostic purposes. Here, we report CAIX expression in multiple tumor types and provide in vitro and in vivo evaluations of 68 Ga-labeled DPI-4452 ([68 Ga]Ga-DPI-4452) and 177 Lu-labeled DPI-4452 ([177 Lu]Lu-DPI-4452)...
March 21, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38514082/quantitative-brain-amyloid-pet
#50
JOURNAL ARTICLE
William J Jagust, Venkata S Mattay, Daniel M Krainak, Sue-Jane Wang, Lora D Weidner, A Alex Hofling, Hayoung Koo, Pamela Hsieh, Phillip H Kuo, Gill Farrar, Libero Marzella
Since the development of amyloid tracers for PET imaging, there has been interest in quantifying amyloid burden in the brains of patients with Alzheimer disease. Quantitative amyloid PET imaging is poised to become a valuable approach in disease staging, theranostics, monitoring, and as an outcome measure for interventional studies. Yet, there are significant challenges and hurdles to overcome before it can be implemented into widespread clinical practice. On November 17, 2022, the U.S. Food and Drug Administration, Society of Nuclear Medicine and Molecular Imaging, and Medical Imaging and Technology Alliance cosponsored a public workshop comprising experts from academia, industry, and government agencies to discuss the role of quantitative brain amyloid PET imaging in staging, prognosis, and longitudinal assessment of Alzheimer disease...
March 21, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38514081/-18-f-bms-986229-pet-to-assess-programmed-death-ligand-1-status-in-gastroesophageal-cancer
#51
JOURNAL ARTICLE
Samuel L Cytryn, Neeta Pandit-Taskar, Melissa A Lumish, Steven B Maron, Ping Gu, Geoffrey Y Ku, Joanne F Chou, Marinela Capanu, Ariel Antoine, Diane Loegel, Lara Feder, Steven Philemond, Serge K Lyashchenko, Jason S Lewis, Viktoriya Paroder, Amitabh Srivastava, Laura H Tang, Heiko Schoder, Yelena Y Janjigian
Anti-programmed death 1 (PD-1) inhibitors are the standard of care for advanced gastroesophageal cancer. Although recommendations and approval by regulatory agencies are often based on programmed death ligand 1 (PD-L1) expression, pathologic assessments of PD-L1 status have several limitations. Single-site biopsies do not adequately capture disease heterogeneity within individual tumor lesions or among several lesions within the same patient, the PD-L1 combined positive score is a dynamic biomarker subject to evolution throughout a patient's disease course, and repeated biopsies are invasive and not always feasible...
March 21, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38485278/the-value-of-68-ga-psma-pet-mri-for-classifying-patients-with-pi-rads-3-lesions-on-multiparametric-mri-a-prospective-single-center-study
#52
JOURNAL ARTICLE
Jingyan Shi, Danyan Li, Mengxia Chen, Yao Fu, Shan Peng, Qing Zhang, Jing Liang, Qun Lu, Jiaming Lu, Shuyue Ai, Feng Wang, Xuefeng Qiu, Hongqian Guo
Prostate Imaging Reporting and Data System (PI-RADS) category 3 lesions remain a diagnostic challenge for detecting clinically significant prostate cancer (csPCa). This article evaluates the added value of 68 Ga-labeled prostate-specific membrane antigen-11 (68 Ga-PSMA) PET/MRI in classifying PI-RADS 3 lesions to avoid unnecessary biopsies. Methods: Sixty biopsy-naïve men with PI-RADS 3 lesions on multiparametric MRI were prospectively enrolled between February 2020 and October 2022. In all, 56 participants underwent 68 Ga-PSMA PET/MRI and prostate systematic biopsy...
March 14, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38485277/strong-correlation-between-suv-max-on-psma-pet-ct-and-numeric-drop-in-%C3%AE-probe-signal-for-intraoperative-identification-of-prostate-cancer-lesions
#53
JOURNAL ARTICLE
Anne-Claire Berrens, Malou A Sorbi, Maarten L Donswijk, Hilda A de Barros, Samaneh Azargoshasb, Matthias N van Oosterom, Daphne D D Rietbergen, Elise M Bekers, Henk G van der Poel, Fijs W B van Leeuwen, Pim J van Leeuwen
Prostate-specific membrane antigen (PSMA) PET is used to select patients with recurrent prostate cancer for metastasis-directed therapy. A surgical approach can be achieved through radioguided surgery (RGS), using a Drop-In γ-probe that traces lesions that accumulate the radioactive signal. With the aim of guiding patient selection for salvage surgery, we studied the correlation between the SUVmax of lesions on preoperative PSMA PET/CT and their intraoperative counts/s measured using the Drop-In γ-probe...
March 14, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38485276/-68-ga-fapi-pet-ct-as-an-alternative-to-18-f-fdg-pet-ct-in-the-imaging-of-invasive-lobular-breast-carcinoma
#54
JOURNAL ARTICLE
Ertan Sahin, Tulay Kus, Alper Aytekin, Evren Uzun, Umut Elboga, Latif Yilmaz, Yusuf B Cayirli, Merve Okuyan, Vuslat Cimen, Ufuk Cimen
Accurate staging of invasive lobular carcinoma (ILC), a subtype of breast cancer, is vital for effective clinical management. Although 18 F-FDG PET/CT is a commonly used tool, its efficacy varies across different histologic subtypes. To mitigate this challenge, our investigation delves into the potential utility of 68 Ga-fibroblast activation protein inhibitor (FAPI) PET/CT as an alternative for staging ILC, aiming to address a significant research gap using a more expansive patient cohort than the smaller samples commonly found in the existing literature...
March 14, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38485275/-18-f-fdg-pet-ct-signal-correlates-with-neoangiogenesis-markers-in-patients-with-fibrotic-interstitial-lung-disease-who-underwent-lung-biopsy-implication-for-the-use-of-pet-ct-in-diffuse-lung-diseases
#55
JOURNAL ARTICLE
Joanna C Porter, Balaji Ganeshan, Thida Win, Francesco Fraioli, Saif Khan, Manuel Rodriguez-Justo, Raymond Endozo, Robert I Shortman, Luke R Hoy, Toby M Maher, Ashley M Groves
The use of [18 F]FDG PET/CT as a biomarker in diffuse lung diseases is increasingly recognized. We investigated the correlation between [18 F]FDG uptake with histologic markers on lung biopsy of patients with fibrotic interstitial lung disease (fILD). Methods: We recruited 18 patients with fILD awaiting lung biopsy for [18 F]FDG PET/CT. We derived a target-to-background ratio (TBR) of maximum pulmonary uptake of [18 F]FDG (SUVmax ) divided by the lung background (SUVmin ). Consecutive paraffin-embedded lung biopsy sections were immunostained for alveolar and interstitial macrophages (CD68), microvessel density (MVD) (CD31 and CD105/endoglin), and glucose transporter 1...
March 14, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38485274/real-world-experience-with-177-lu-psma-617-radioligand-therapy-after-food-and-drug-administration-approval
#56
JOURNAL ARTICLE
Abuzar Moradi Tuchayi, Surekha Yadav, Fei Jiang, Sarasa T Kim, Rachelle K Saelee, Amanda Morley, Roxanna Juarez, Courtney Lawhn-Heath, Yingbing Wang, Ivan de Kouchkovsky, Thomas A Hope
We report our initial real-world experience with 177 Lu-PSMA-617 radioligand therapy. Methods: We performed a retrospective review of patients treated with 177 Lu-PSMA-617. Pretreatment PSMA PET, laboratory findings, overall survival, a fall in prostate-specific antigen by 50% (PSA50), and toxicities were evaluated. Results: Ninety-nine patients were included. Sixty patients achieved a PSA50. Seven of 18 (39%) patients who did not meet the TheraP PSMA imaging criteria achieved a PSA50. Nineteen of 31 (61%) patients who did not meet the VISION laboratory criteria achieved a PSA50...
March 14, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38485273/efficacy-of-67-cu-cu-eb-tate-theranostic-against-somatostatin-receptor-subtype-2-positive-neuroendocrine-tumors
#57
JOURNAL ARTICLE
Fabrice Ngoh Njotu, Jessica Pougoue Ketchemen, Anjong Florence Tikum, Hanan Babeker, Brian D Gray, Koon Y Pak, Maruti Uppalapati, Humphrey Fonge
β- -emitting 177 Lu-octreotate is an approved somatostatin receptor subtype 2 (SSTR2)-directed peptide receptor radionuclide therapy for the treatment of gastroenteropancreatic neuroendocrine tumors (NETs). However,177 Lu-octreotate has fast pharmacokinetics, requiring up to 4 treatment doses. Moreover, 177 Lu is less than ideal for theranostics because of the low branching ratio of its γ-emissions, which limits its SPECT imaging capability. Compared with 177 Lu, 67 Cu has better decay properties for use as a theranostic...
March 14, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38485272/can-internal-carotid-arteries-be-used-for-noninvasive-quantification-of-brain-pet-studies
#58
JOURNAL ARTICLE
Laura Providência, Chris W J van der Weijden, Philipp Mohr, Joyce van Sluis, Johannes H van Snick, Riemer H J A Slart, Rudi A J O Dierckx, Adriaan A Lammertsma, Charalampos Tsoumpas
Because of the limited axial field of view of conventional PET scanners, the internal carotid arteries are commonly used to obtain an image-derived input function (IDIF) in quantitative brain PET. However, time-activity curves extracted from the internal carotids are prone to partial-volume effects due to the limited PET resolution. This study aimed to assess the use of the internal carotids for quantifying brain glucose metabolism before and after partial-volume correction. Methods: Dynamic [18 F]FDG images were acquired on a 106-cm-long PET scanner, and quantification was performed with a 2-tissue-compartment model and Patlak analysis using an IDIF extracted from the internal carotids...
March 14, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38485271/interrogating-the-theranostic-capacity-of-a-muc16-targeted-antibody-for-ovarian-cancer
#59
JOURNAL ARTICLE
Kyeara N Mack, Zachary V Samuels, Lukas M Carter, Tara D Viray, Komal Mandleywala, Cory L Brooks, Michael A Hollingsworth, Prakash Radhakrishnan, Jason S Lewis
Aberrantly expressed glycans on mucins such as mucin-16 (MUC16) are implicated in the biology that promotes ovarian cancer (OC) malignancy. Here, we investigated the theranostic potential of a humanized antibody, huAR9.6, targeting fully glycosylated and hypoglycosylated MUC16 isoforms. Methods: In vitro and in vivo targeting of the diagnostic radiotracer [89 Zr]Zr-DFO-huAR9.6 was investigated via binding experiments, immuno-PET imaging, and biodistribution studies on OC mouse models. Ovarian xenografts were used to determine the safety and efficacy of the therapeutic version, [177 Lu]Lu-CHX-A″-DTPA-huAR9...
March 14, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38485270/an-18-f-fdg-pet-ct-and-mean-lung-dose-model-to-predict-early-radiation-pneumonitis-in-stage-iii-non-small-cell-lung-cancer-patients-treated-with-chemoradiation-and-immunotherapy
#60
JOURNAL ARTICLE
Maria Thor, Chen Lee, Lian Sun, Purvi Patel, Aditya Apte, Milan Grkovski, Annemarie F Shepherd, Daphna Y Gelblum, Abraham J Wu, Charles B Simone, Jamie E Chaft, Andreas Rimner, Daniel R Gomez, Joseph O Deasy, Narek Shaverdian
Radiation pneumonitis (RP) that develops early (i.e., within 3 mo) (RPEarly ) after completion of concurrent chemoradiation (cCRT) leads to treatment discontinuation and poorer survival for patients with stage III non-small cell lung cancer. Since no RPEarly risk model exists, we explored whether published RP models and pretreatment 18 F-FDG PET/CT-derived features predict RPEarly Methods: One hundred sixty patients with stage III non-small cell lung cancer treated with cCRT and consolidative immunotherapy were analyzed for RPEarly Three published RP models that included the mean lung dose (MLD) and patient characteristics were examined...
March 14, 2024: Journal of Nuclear Medicine
journal
journal
20164
3
4
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.